A Phase I, Open-Label, Randomized, Single-Center, Parallel Design Study Evaluating Pharmacokinetics of CaPre (Omega-3 Phospholipid) Following Single and Multiple Oral Doses in Healthy Volunteers

Trial Profile

A Phase I, Open-Label, Randomized, Single-Center, Parallel Design Study Evaluating Pharmacokinetics of CaPre (Omega-3 Phospholipid) Following Single and Multiple Oral Doses in Healthy Volunteers

Completed
Phase of Trial: Phase I

Latest Information Update: 22 Aug 2017

At a glance

  • Drugs Omega-3 phospholipid (Primary)
  • Indications Hypertriglyceridaemia
  • Focus Pharmacokinetics
  • Most Recent Events

    • 22 Aug 2017 New trial record
    • 14 Aug 2017 According to an Acasti Pharma media release, select data from this and other studies (TRIFECTA, COLT and PMRI2016-4010) will be submitted for publication in a peer-reviewed journal.
    • 14 Aug 2017 Results from this study were included in an oral presentation at the International Academy of Cardiology Annual Scientific Sessions 22nd World Congress on Heart Disease (WCHD), according to an Acasti Pharma media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top